AER 1165478 is a spontaneous case, received on 05/Dec/2012 from a consumer (son-in-law) and concerns a 
female patient of unknown age who experienced progressive multifocal leukoencephalopathy (PML) and died while 
being treated with rituximab (Rituxan).
No medical history, concurrent condition, concomitant medications or past drugs were reported.
On an unspecified date, the patient started therapy with rituximab (dosage regimen not reported) for unknown 
indication. Subsequently, she experienced Progressive multifocal leukoencephalopathy on an unspecified date. 
Later, it was reported that she passed away in(b) (6)  within 1-2 months of diagnosis. Cause of death was not 
reported. No autopsy information was provided.
At the time of this report, the outcome of the event progressive multifocal leukoencephalopathy was not reported 
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 346 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
and it was unknown whether therapy with rituximab was ongoing or not.
The reporter did not provide causality for the events progressive multifocal leukoencephalopathy and death with 
rituximab.
The company assessed the event progressive multifocal leukoencephalopathy as medically significant.
No further information was provided.
Additional information received on 17/Sep/2014. Following information was added to the case: New event added as
death.